-
1 month ago | 
mdpi.com | Olivia Norato |Sarah Velez |Arbohnor Lleshi |Gordon Lam
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Sep 26, 2024 | 
hcplive.com | Gordon Lam |Leonard Calabrese |Grace Wright |Jeffrey A Sparks |Catherine Bakewell
September 26, 2024By Panelists discuss how their approaches to treating patients with rheumatoid arthritis focus on personalized strategies that prioritize achieving remission while carefully monitoring safety and efficacy outcomes. Video content above is prompted by the following:Can each of you provide closing remarks on how you treat your own patients to achieve remission? Related Content Related Content
-
Sep 26, 2024 | 
hcplive.com | Gordon Lam |Leonard Calabrese |Grace Wright |Jeffrey A Sparks |Catherine Bakewell
September 26, 2024By Panelists discuss how the findings from the ORAL Surveillance study regarding cardiovascular and cancer risks associated with tofacitinib have influenced perceptions of JAK inhibitors, emphasizing the need to balance safety concerns with their efficacy in managing rheumatoid arthritis.
-
Sep 19, 2024 | 
hcplive.com | Gordon Lam |Leonard Calabrese |Grace Wright |Jeffrey A Sparks |Catherine Bakewell
September 19, 2024By Panelists discuss how continued cycling of tumor necrosis factor inhibitors (TNFis) without achieving remission can lead to complications like irreversible joint erosion, significantly diminishing patient quality of life, and explore why providers may persist with TNFis despite failure, access barriers to switching mechanisms of action, and treatment considerations for patients whose initial positive response to TNFis declines over time.
-
Sep 19, 2024 | 
hcplive.com | Gordon Lam |Leonard Calabrese |Grace Wright |Jeffrey A Sparks |Catherine Bakewell
September 19, 2024By Panelists discuss how switching to a biologic with a different mechanism of action can enhance clinical outcomes in patients with inadequate responses to tumor necrosis factor inhibitors. Video content above is prompted by the following:What outcomes are associated with switching to a biologic with a different mechanism of action (MOA) rather than cycling a tumor necrosis factor inhibitor (TNFi)?
-
Sep 12, 2024 | 
hcplive.com | Gordon Lam |Leonard Calabrese |Grace Wright |Jeffrey A Sparks |Catherine Bakewell
September 12, 2024By Panelists discuss how JAK inhibitors and TNF inhibitors differ in administration, efficacy, and safety due to their unique characteristics and mechanisms of action, with further variations in binding activities within the TNFi class impacting clinical outcomes.
-
Sep 12, 2024 | 
hcplive.com | Gordon Lam |Leonard Calabrese |Grace Wright |Jeffrey A Sparks |Catherine Bakewell
September 12, 2024By Panelists discuss how the varying selectivity of JAK inhibitors—such as tofacitinib's broad inhibition of JAK1/JAK2/JAK3, baricitinib's inhibition of JAK1/JAK2, and upadacitinib's focus on JAK1—affects dose-related toxicity and overall treatment safety. Video content above is prompted by the following:Mechanism of action also differs in the Janus kinase (JAK) inhibitor class. Tofacitinib inhibits JAK1/JAK2/JAK3, baricitinib inhibits JAK1/JAK2, and upadacitinib inhibits JAK1.
-
Sep 5, 2024 | 
hcplive.com | Gordon Lam |Leonard Calabrese |Grace Wright |Jeffrey A Sparks |Catherine Bakewell
September 5, 2024By Panelists discuss advanced treatment options for rheumatoid arthritis, focusing on the SELECT-COMPARE trial's head-to-head data of upadacitinib versus adalimumab, the use of upadacitinib in active RA refractory to biologics (SELECT-BEYOND trial), and the remission rates of upadacitinib compared to abatacept (SELECT-CHOICE trial).
-
Sep 5, 2024 | 
hcplive.com | Gordon Lam |Leonard Calabrese |Grace Wright |Jeffrey A Sparks |Catherine Bakewell
September 5, 2024By Panelists discuss how head-to-head clinical trial data shape their treatment decisions, the significance of consistent remission rates across different patient populations, and the frequency with which remission data influence their choices to switch therapies. Video content above is prompted by the following:How do head-to-head data affect your treatment decisions? What does consistency of remission across patient types mean to you?
-
Aug 29, 2024 | 
hcplive.com | Gordon Lam |Leonard Calabrese |Grace Wright |Jeffrey A Sparks |Catherine Bakewell
August 29, 2024By Experts discuss American College of Rheumatology guidelines on transitioning patients from TNF inhibitors to non-TNF targeted therapies like Janus kinase inhibitors, as well as factors influencing treatment switching decisions in clinical practice.
